CordenPharma Expands Manufacturing Capacities for Veterinary Drug Products

  • CordenPharma's Plankstadt facility. Former AstraZeneca Plankstadt plant acquired by ICIG to become CordenPharma Plankstadt GmbH in 2007/08. © CordenPharma InternationalCordenPharma's Plankstadt facility. Former AstraZeneca Plankstadt plant acquired by ICIG to become CordenPharma Plankstadt GmbH in 2007/08. © CordenPharma International

CordenPharma, a contract manufacturer for APIs, drug products and packaging, announced the design and installment of a new manufacturing line at its Plankstadt, Germany site. The new line is part of a production plant that is dedicated to veterinary drug products, the company said.

According to CordenPharma the expansion of manufacturing capabilities at Plankstadt is the result of a recently signed long-term custom manufacturing agreement for an animal health application. The name of the customer was not disclosed. Work is scheduled to begin in the second half of 2017, with a targeted mechanical completion by Q2 of 2018 and commercial supply for the global launch campaign planned to start in the second half of 2018.

“This is an extremely important and significant investment for CordenPharma Plankstadt. This new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of Veterinary Drug Products. This is a unique opportunity in the industry,” said Frank Hähner, managing director of CordenPharma Plankstadt.

You may also be interested in

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.